.Nature Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medicine conjugate (ADC) tisotumab vedotin resulted in enhanced progression-free as well as general survival, resulting in FDA commendation and also a new therapy choice for patients.